Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Background: The signal transducer and activator of transcription 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results